Abstract:Neoadjuvant chemotherapy is increasingly widely used in the treatment of cancer, and 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) and PET/CT play a role in the early assessment of response to neoadjuvant chemotherapy, including tumor restaging, drug selection and prognosis prediction, which facilitate the design of therapeutic regimen and reduction of ineffective therapy. The progress of application of 18F-FDG PET and PET/CT in the assessment of response of tumor to neoadjuvant chemotherapy is reviewed in this paper.

Progress of Application of 18F-FDG PET and PET/CT in Assessment of Response of Tumor to Neoadjuvant Chemotherapy